Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma.

192 Ir) source for a total dose of 36 Gy over six fractions. The tumours showed regression, but recurred within 1 year. Further treatment options, including radiotherapy, surgery and photodynamic therapy, were discussed. The patient subsequently consented to photodynamic therapy, which was carried out in an outpatient clinic. We used a new generation photosensitiser, Fotolon (Haemato-science GmbH, Luckenwalde, Germany), which comprises chlorin e6 and polyvinylpyrrolidone (molecular weight 12 000) in the ratio of 1:1. Unlike fi rst generation photosensitisers, which rendered patients light sensitive for up to a few weeks, Fotolon clears rapidly from the body within 24 h. 1 Fotolon was prepared freshly by dissolving 0·2 g of Fotolon in 100 mL of 0·9% saline. The preparation was administered intravenously at a dose of 2·0–5·7 mg/kg body weight over 10–20 min. 3 h later, the tumours were irradiated with laser light of wavelength 665 nm (± 3 nm) for a total light dose of 65–200 J/cm², delivered at a fl uence rate of 80–150 mW/cm². The table shows the treatment parameters used during each administration. We did not note any side-eff ects or complications during or after treatment, other than transient pain at the